Table 1 Baseline characteristics of the training and validation cohorts.

From: AI derived ECG global longitudinal strain compared to echocardiographic measurements

 

Training cohort 1

Training cohort 2

Training cohort 3

Training cohort 4

p value (Training Cohort 1–4)

Training cohort (total)

Validation cohort

p value (Training vs. Validation)

STRATS-AHF (Hospital A)

ARNI cohort (Initial)

ARNI cohort (Follow-up)

Three-chamber strain cohort

Hospital A (Total)

Hospital B

(STRATS-AHF)

(N = 1,528)

(N = 343)

(N = 334)

(N = 677)

(N = 2,882)

(N = 1,186)

Age (years)

72.3 ± 13.1

64.6 ± 13.7

64.8 ± 14.1

68.4 ± 14.4

< 0.001

69.6 ± 13.9

69.0 ± 14.8

0.246

Male sex

763 (49.9%)

252 (73.5%)

244 (73.1%)

403 (59.5%)

< 0.001

1662 (57.7%)

681 (57.4%)

0.912

SBP (mmHg)

133.4 ± 29.1

119.1 ± 18.0

118.4 ± 17.4

128.2 ± 18.8

< 0.001

128.8 ± 25.3

129.0 ± 27.4

0.826

DBP (mmHg)

74.8 ± 18.6

71.7 ± 13.9

71.2 ± 3.1

73.7 ± 12.7

< 0.001

73.8 ± 16.3

75.9 ± 16.6

< 0.001

DM

587 (38.4%)

118 (34.4%)

114 (34.1%)

158 (23.3%)

< 0.001

977 (33.9%)

346 (29.2%)

0.004

HTN

1049 (68.7%)

110 (32.1%)

108 (32.3%)

271 (40.0%)

< 0.001

1538 (53.4%)

522 (44.0%)

< 0.001

Prior HF

450 (29.5%)

343 (100.0%)

334 (100.0%)

225 (33.2%)

< 0.001

1352 (46.9%)

812 (68.5%)

< 0.001

Prior CAD

523 (34.2%)

114 (33.2%)

108 (32.3%)

196 (29.0%)

0.111

941 (32.7%)

305 (25.7%)

< 0.001

BUN (mg/dL)

27.6 ± 18.0

22.3 ± 12.7

22.2 ± 12.6

20.6 ± 13.3

< 0.001

24.7 ± 16.1

26.1 ± 17.0

0.023

Creatinine (mg/dL)

1.6 ± 1.8

1.3 ± 1.3

1.3 ± 1.1

1.2 ± 1.4

< 0.001

1.5 ± 1.6

1.7 ± 2.0

< 0.001

LVEDD (mm)

53.0 ± 9.2

60.5 ± 7.7

56.4 ± 8.8

48.6 ± 7.3

< 0.001

53.2 ± 9.3

56.1 ± 9.8

< 0.001

LVESD (mm)

40.3 ± 11.3

51.1 ± 8.7

45.3 ± 10.3

33.4 ± 8.9

< 0.001

40.5 ± 11.6

41.7 ± 12.3

0.012

LVEF (%)

41.5 ± 15.8

27.7 ± 6.8

38.0 ± 11.9

56.7 ± 12.2

< 0.001

43.0 ± 16.3

40.7 ± 15.4

< 0.001

LVMI (g/m2)

135.0 ± 44.2

140.5 ± 37.8

124.6 ± 35.1

104.8 ± 35.3

< 0.001

127.2 ± 42.6

126.6 ± 42.3

0.679

LA diameter (mm)

43.7 ± 8.9

44.2 ± 7.8

41.8 ± 8.6

40.3 ± 8.1

< 0.001

42.7 ± 8.7

48.9 ± 10.5

< 0.001

LAVI (ml/m2)

59.2 ± 32.3

61.6 ± 28.3

53.6 ± 29.1

46.1 ± 26.0

< 0.001

55.8 ± 30.6

64.0 ± 53.8

< 0.001

E velocity (m/s)

0.9 ± 0.4

0.8 ± 0.3

0.7 ± 0.3

0.8 ± 0.3

< 0.001

0.8 ± 0.3

0.9 ± 0.4

< 0.001

E/e’

19.1 ± 10.8

18.9 ± 10.5

15.0 ± 9.0

13.0 ± 7.3

< 0.001

17.1 ± 10.1

19.4 ± 11.0

< 0.001

TR Vmax (m/s)

2.8 ± 0.6

2.7 ± 0.6

2.5 ± 0.5

2.5 ± 0.5

< 0.001

2.7 ± 0.6

3.0 ± 0.6

< 0.001

RVSP (mmHg)

38.6 ± 13.7

36.9 ± 15.0

31.0 ± 11.8

31.8 ± 11.4

< 0.001

36.0 ± 13.5

48.6 ± 15.3

< 0.001

LVGLS (%, absolute)

10.5 ± 4.8

10.2 ± 3.2

12.8 ± 4.4

16.4 ± 4.5

< 0.001

12.1 ± 5.2

10.4 ± 5.2

< 0.001

Vendor

    

< 0.001

  

< 0.001

 GE

964 (63.3%)

0 (0.0%)

0 (0.0%)

168 (24.8%)

 

1132 (51.5%)

547 (46.2%)

 

 Philips

167 (11.0%)

343 (100.0%)

334 (100.0%)

509 (75.2%)

 

676 (30.7%)

266 (22.4%)

 

 Siemens

392 (25.7%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

 

392 (17.8%)

372 (31.4%)

 
  1. BUN blood urea nitrogen, CAD coronary artery disease, DBP diastolic blood pressure, DM diabetes mellitus, HF heart failure, HTN hypertension, LA left atrium, LAVI left atrial volume index, LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, LVESD left ventricular end-systolic dimension, LVGLS, left ventricular global longitudinal strain, LVMI left ventricular mass index, SBP systolic blood pressure, TR tricuspid regurgitation.